Last reviewed · How we verify
Latanoprost, Dorzolamide
This combination reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor (latanoprost) and decreasing aqueous humor production (dorzolamide).
This combination reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor (latanoprost) and decreasing aqueous humor production (dorzolamide). Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Latanoprost, Dorzolamide |
|---|---|
| Also known as | - Latanoprost, a prostaglandin analogue, - Dorzolamide, a potent inhibitor of carbonic anhydrase II |
| Sponsor | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
| Drug class | Prostaglandin analog + Carbonic anhydrase inhibitor combination |
| Target | Prostaglandin F receptor (FP receptor) and Carbonic anhydrase II |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors and enhances drainage of aqueous humor through the uveoscleral pathway. Dorzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary body. Together, these complementary mechanisms provide additive intraocular pressure reduction.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation/discomfort
- Increased iris pigmentation
- Eyelash growth
- Bitter taste (dorzolamide component)
- Blurred vision
Key clinical trials
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? (PHASE4)
- Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (PHASE4)
- Circadian Rhythms of Aqueous Humor Dynamics in Humans (PHASE2)
- A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma (PHASE4)
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: